2018, Number 4
Stratification of the risk of chemotherapy-induced cardiotoxicity: Reply
Full text
Language: Spanish
References: 0
Page: 342-344
PDF size: 306.50 Kb.
Text Extraction
To the Editor
We agree with Rodríguez Ramos1 that adequate prophylaxis and early diagnosis of chemotherapy-induced cardiotoxicity (CIC) will be critically important to reduce or delay the onset of ventricular dysfunction and clinical heart failure in a large part of
the population affected by tumor diseases.
The improved survival in cancer patients, in general, and in advanced disease; the development of
personalized medicine, the incidence of second neoplasms in cancer survivors, therapeutics with longterm medications, the possibility of using new lines
of treatment –locations with more than 4 lines–, the
development of radiotherapy techniques that allow
re-irradiation, the advances in rescue surgery,
among other reasons that show the transition of the
disease towards chronicity, grant urgency to develop adequate strategies of prevention and treatment
of the patient to avoid or delay the damage or myocardial affection generated by the exposure to
chemotherapeutic agents.